Lv6
2849 积分 2022-03-04 加入
Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials
22天前
已完结
How should the efficacy of novel treatments be assessed in survival trials?
6个月前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
6个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
9个月前
已完结
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIB trial
9个月前
已完结
Common misconceptions of randomized controlled trials in oncology
1年前
已完结
皖公网安备34019202002308
